RT Journal Article
SR Electronic
T1 Evaluation of the costs of care for pediatric patients hospitalized for RSV: a retrospective cohort study in Belgium
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.21.24317618
DO 10.1101/2024.11.21.24317618
A1 Tilmanne, Anne
A1 Pirson, Magali
A1 Leclercq, Pol
A1 Van Den Bulcke, Julie
A1 Bruyneel, Arnaud
YR 2024
UL http://medrxiv.org/content/early/2024/11/22/2024.11.21.24317618.abstract
AB Objectives This study aimed to evaluate the costs of respiratory-syncytial virus (RSV)-related hospitalizations in children under 3 years old in Belgium for hospitals and health insurance, and to identify factors influencing costs.Study design This retrospective cohort study used data from 16 French-speaking hospitals in Belgium, covering January 1, 2018, to December 31, 2019. RSV diagnoses for children under three were identified using International Classification of Diseases-Tenth Revision (ICD-10) codes, resulting in 2,176 hospitalizations analyzed for cost assessment. Hospital and health insurance costs were derived from administrative and billing data, adjusted for inflation, and analyzed using descriptive and inferential statistics, including regression models to assess cost factors.Results RSV prevalence among pediatric hospitalizations peaked at 12.9% in 2018 and 10.0% in 2019, with children under 3 years showing a prevalence of 16.7% both years. Of the 2,176 RSV-related hospitalizations, 61.8% were in children under one year, and 28.6% had readmissions within a year. The median length of stay (LOS) was 3.67 days, with a median hospital cost of €2,924 and a median health insurance cost of €2,221 per stay. Factors associated with higher costs included longer LOS, severe diagnosis-related group category, pediatric intensive care unit admission, and non-invasive ventilation use, with costs generally lower for children aged 1-2 years.Conclusions This study highlights the significant financial burden of RSV hospitalization in Belgium, with costs exceeding €25 million annually. This emphasizes the need for preventive measures and better resource allocation to reduce the economic impact of RSV on healthcare systems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The inpatient records used in the retrospective study were fully anonymized by the hospitals and the research team did not have any access to medical files. The study was approved by the Ethics Committee of the Erasmus Hospital in Brussels (reference: N2023/047). Signed informed consent was obtained from all individual participants included in this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe dataset used and analyzed in this manuscript is available from the corresponding author upon reasonable request.APR-DRGall patients refined disease-related groupCIconfidence intervalDRGdisease-related groupICUintensive care unit;ICD-10International Classification of Diseases-10th revisionIQRinterquartile rangeLOSlength of stayNICUneonatal intensive care unitPICUpediatric intensive care unitRSVrespiratory syncytial virusSOIseverity of illness